Business
Skye Bioscience Highlights Attributes of its Peripherally-restricted CB1 Inhibitor Antibody at Keystone Obesity Conference
SAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today presented a poster titled "Investigating the Efficacy of Nimacimab Alone or in Combination with Tirzepatide, and as a Maintenance Therapy Post Tirzepatide Discontinuation in a Diet-Induced Obesity (DIO) Mouse Model" at Keystone’s conference, Obesity Therapeutics: Unlo
About this update from Skye Bioscience, Inc.
[{"type":"image","alt":"Skye Bioscience, Inc.","displaySize":"","headline":null,"caption":"Skye Bioscience, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":141,"url":"https://media.zenfs.com/en/globenewswire.com/90c497d694309d41a1d6fa12ddb2a61c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/7pwAl2G8ZGCyG39CbcNdmw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5NztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/90c497d694309d41a1d6fa12ddb2a61c","width":300,"height":141}},"lazy":false},{"type":"text","content":"SAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today presented a poster titled "Investigating the Efficacy of Nimacimab Alone or in Combination with Tirzepatide, and as a Maintenance Therapy Post Tirzepatide Discontinuation in a Diet-Induced Obesity (DIO) Mouse Model" at Keystone’s conference, Obesity Therapeutics: Unlocking Benefits and Minimizing Side Effects.","length":553,"tagName":"p"},{"type":"text","content":"Skye’s presentation addressed the following questions regarding the ability of its peripherally-restricted CB1-inhibitor antibody:","length":130,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Can nimacimab enhance optimal and suboptimal doses of incretin agonists?","length":72,"tagName":"p"}]},{"val":[{"type":"text","content":"How durable is nimacimab’s effect on weight loss after treatment discontinuation?","length":81,"tagName":"p"}]},{"val":[{"type":"text","content":"Can nimacimab be used as a maintenance therapy after tirzepatide discontinuation?","length":81,"tagName":"p"}]},{"val":[{"type":"text","content":"Is caloric-restriction the primary mechanism of nimacimab-driven weight loss?","length":77,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":311,"olType":false},{"type":"text","content":"Key takeaways from the DIO studies:","length":35,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Nimacimab showed significant additive weight loss effects when combined with suboptimal or clinically active dose levels of tirzepatide (39% and 46% weight loss respectively).","length":175,"tagName":"p"}]},{"val":[{"type":"text","content":"Nimacimab weight l...